ARS Pharmaceuticals (SPRY) Competitors

ARS Pharmaceuticals (NASDAQ:SPRY) and ADMA Biologics (NASDAQ:ADMA) are both medical companies, but which is the better stock? We will compare the two companies based on the strength of their institutional ownership, profitability, earnings, dividends, media sentiment, valuation, risk and analyst recommendations.

Is SPRY or ADMA more profitable?

ADMA Biologics has a net margin of 44.06% compared to ARS Pharmaceuticals' net margin of -42.74%. ADMA Biologics' return on equity of 41.01% beat ARS Pharmaceuticals' return on equity.

Company	Net Margins	Return on Equity	Return on Assets
ARS Pharmaceuticals	-42.74%	-21.85%	-15.88%
ADMA Biologics	44.06%	41.01%	28.47%

Which has more volatility & risk, SPRY or ADMA?

ARS Pharmaceuticals has a beta of 0.84, suggesting that its stock price is 16% less volatile than the S&P 500. Comparatively, ADMA Biologics has a beta of 0.47, suggesting that its stock price is 53% less volatile than the S&P 500.

Which has higher earnings & valuation, SPRY or ADMA?

ADMA Biologics has higher revenue and earnings than ARS Pharmaceuticals. ARS Pharmaceuticals is trading at a lower price-to-earnings ratio than ADMA Biologics, indicating that it is currently the more affordable of the two stocks.

Company	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
ARS Pharmaceuticals	$89.15M	11.43	$8M	-$0.49	-21.04
ADMA Biologics	$426.45M	8.20	$197.67M	$0.86	17.05

Do analysts prefer SPRY or ADMA?

ARS Pharmaceuticals presently has a consensus target price of $33.17, indicating a potential upside of 221.69%. ADMA Biologics has a consensus target price of $27.67, indicating a potential upside of 88.72%. Given ARS Pharmaceuticals' higher possible upside, equities analysts plainly believe ARS Pharmaceuticals is more favorable than ADMA Biologics.

Company	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
ARS Pharmaceuticals	1 Sell rating(s)	0 Hold rating(s)	6 Buy rating(s)	1 Strong Buy rating(s)	2.88
ADMA Biologics	0 Sell rating(s)	0 Hold rating(s)	3 Buy rating(s)	1 Strong Buy rating(s)	3.25

Does the media refer more to SPRY or ADMA?

In the previous week, ARS Pharmaceuticals had 12 more articles in the media than ADMA Biologics. MarketBeat recorded 15 mentions for ARS Pharmaceuticals and 3 mentions for ADMA Biologics. ADMA Biologics' average media sentiment score of 1.25 beat ARS Pharmaceuticals' score of -0.13 indicating that ADMA Biologics is being referred to more favorably in the news media.

Company	Very Positive	Positive	Neutral	Negative	Very Negative	Overall Sentiment
ARS Pharmaceuticals	3 Very Positive mention(s)	1 Positive mention(s)	4 Neutral mention(s)	0 Negative mention(s)	0 Very Negative mention(s)	Neutral
ADMA Biologics	2 Very Positive mention(s)	0 Positive mention(s)	1 Neutral mention(s)	0 Negative mention(s)	0 Very Negative mention(s)	Positive

Do institutionals and insiders believe in SPRY or ADMA?

68.2% of ARS Pharmaceuticals shares are owned by institutional investors. Comparatively, 75.7% of ADMA Biologics shares are owned by institutional investors. 33.5% of ARS Pharmaceuticals shares are owned by company insiders. Comparatively, 3.5% of ADMA Biologics shares are owned by company insiders. Strong institutional ownership is an indication that hedge funds, large money managers and endowments believe a stock will outperform the market over the long term.

Summary

ADMA Biologics beats ARS Pharmaceuticals on 10 of the 16 factors compared between the two stocks.